Webinar Technology

Generating CRISPR mouse models: Challenges and solutions

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Generating CRISPR mouse models: Challenges and solutions

Recorded 17 May 2017


The discovery of the CRISPR/Cas9 system in bacteria has ignited the world of gene editing. It has been applied to the modification of a growing range of organisms, with none found yet that can resist its powers. In particular, CRISPR technology has revolutionized the process for creating genetically modified mice—the workhorses for in vivo cancer research—allowing for shorter timelines and in many cases, more efficient procedures. In this webinar, our expert panel will discuss the strengths and benefits of CRISPR technology, how it differs from more traditional techniques, and some of the specific challenges it creates. They will share their at-the-bench experiences with viewers, providing practical, actionable information for researchers wanting to apply CRISPR technology to mouse-model generation, particularly for use in cancer research.

During the webinar, the panelists will:

  • Highlight the workflow for using CRISPR to generate genetically modified mice
  • Provide examples of models of human disease created using CRISPR
  • Discuss the challenges in applying the CRISPR system and how they have been overcome.

This webinar will last for approximately 60 minutes.

Speaker bios

Rudolf Jaenisch, Ph.D.

Massachusetts Institute of Technology
Cambridge, MA

Dr. Jaenisch is a founding member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology. He is a pioneer in creating transgenic mice, some of which have led to important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities; and he has explored basic questions such as the role of DNA modification, genomic imprinting, and X-chromosome inactivation. His laboratory is renowned for its expertise in cloning mice and in studying the myriad factors contributing to the success and failure of cellular reprogramming. Recently the lab has focused on using the iPS cell system to study diseases such as Alzheimer’s, Parkinson’s, and autism. Dr. Jaenisch is a member of the National Academy of Sciences and the International Society for Stem Cell Research. He was honored with the Boehringer Mannheim Molecular Bioanalytics Prize in 1996, received the first ever Gruber Foundation Genetics Prize in 2001, won the Robert Koch Prize for Excellence in Scientific Achievement in 2002, and the March of Dimes Prize in Developmental Biology in 2015, and was a recipient of the U.S. National Medal of Science in 2011. In 2014 he served as president of the International Society for Stem Cell Research.

David S. Grass, Ph.D.

Jackson Laboratory
Bar Harbor, ME

Dr. Grass has been involved in the generation of genetically modified mice for more than 25 years. He received his Ph.D. in molecular biology from Columbia University in New York, and was a postdoctoral fellow at the Sloan Kettering Institute, where his research focus was molecular immunology. He spent an extensive amount of time at a small biotech company (Xenogen Biosciences, previously known as DNX), where his groups were responsible for the generation of genetically modified animal models as well as phenotyping and in vivo compound assessment. Dr. Grass is currently senior director, genetic engineering, transgenic genotyping, and reproductive sciences at The Jackson Laboratory, with responsibility for the model generation program there.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here